A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
Open Access
- 26 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we identified two genes (ANLN and ARNTL2) from multiple gene expression data sets, and developed a two-mRNA-based signature that can effectively distinguish high- and low-risk patients and predict patients’ response to immunotherapy. Furthermore, taking full advantage of the complementary value of clinical and molecular features, we combined the immune prognostic signature with clinical features to construct and validate a nomogram that can predict the probability of high tumor mutational burden (>10 mutations per megabyte). This may improve the estimation of immunotherapy response in LUAD patients, and provide a new perspective for clinical screening of immunotherapy beneficiaries.This publication has 31 references indexed in Scilit:
- The biological functions and clinical applications of exosomes in lung cancerCellular and Molecular Life Sciences, 2019
- Erratum: Corrigendum: Classification and characterization of microsatellite instability across 18 cancer typesNature Medicine, 2018
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersMolecular Cancer Therapeutics, 2017
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsBritish Journal of Cancer, 2014
- The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel PerspectiveCancer Research, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironmentCancer Cell, 2006